TMCC3 and neoplasm: The results indicated that RFS correlated with patients aged ≥50 years (HR: 2.74, 95% CI: 1.43–5.24, p = 0.002) and Grade III (HR: 1.89, 95% CI: 1.04–3.46, p = 0.038), and higher expression of TMCC3 in tumor (HR: 3.32, 95% CI: 1.89–5.83, p = 0.001) (Table 2).